全文获取类型
收费全文 | 3731篇 |
免费 | 254篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 166篇 |
妇产科学 | 28篇 |
基础医学 | 353篇 |
口腔科学 | 105篇 |
临床医学 | 272篇 |
内科学 | 965篇 |
皮肤病学 | 27篇 |
神经病学 | 236篇 |
特种医学 | 84篇 |
外科学 | 563篇 |
综合类 | 69篇 |
预防医学 | 114篇 |
眼科学 | 437篇 |
药学 | 195篇 |
中国医学 | 3篇 |
肿瘤学 | 299篇 |
出版年
2023年 | 36篇 |
2022年 | 102篇 |
2021年 | 181篇 |
2020年 | 115篇 |
2019年 | 148篇 |
2018年 | 182篇 |
2017年 | 93篇 |
2016年 | 104篇 |
2015年 | 128篇 |
2014年 | 204篇 |
2013年 | 205篇 |
2012年 | 310篇 |
2011年 | 260篇 |
2010年 | 151篇 |
2009年 | 140篇 |
2008年 | 221篇 |
2007年 | 212篇 |
2006年 | 168篇 |
2005年 | 160篇 |
2004年 | 134篇 |
2003年 | 111篇 |
2002年 | 117篇 |
2001年 | 64篇 |
2000年 | 33篇 |
1999年 | 29篇 |
1998年 | 14篇 |
1997年 | 25篇 |
1996年 | 8篇 |
1993年 | 10篇 |
1992年 | 24篇 |
1991年 | 11篇 |
1990年 | 22篇 |
1989年 | 20篇 |
1988年 | 19篇 |
1987年 | 18篇 |
1986年 | 11篇 |
1985年 | 13篇 |
1984年 | 11篇 |
1983年 | 17篇 |
1981年 | 13篇 |
1980年 | 12篇 |
1979年 | 11篇 |
1978年 | 7篇 |
1977年 | 9篇 |
1976年 | 13篇 |
1975年 | 9篇 |
1973年 | 7篇 |
1972年 | 10篇 |
1968年 | 9篇 |
1965年 | 10篇 |
排序方式: 共有3988条查询结果,搜索用时 15 毫秒
51.
Diabetes is a progressive disease affecting millions of people worldwide. There are several medications and treatment options to improve the life quality of people with diabetes. One of the strategies for the treatment of diabetes could be the use of human pluripotent stem cells or induced pluripotent stem cells. The recent advances in differentiation of stem cells into insulin-secreting beta-like cells in vitro make the transplantation of the stem cell-derived beta-like cells an attractive approach for treatment of type 1 and type 2 diabetes. While stem cell-derived beta-like cells provide an unlimited cell source for beta cell replacement therapies, these cells can also be used as a platform for drug screening or modeling diseases. 相似文献
52.
53.
The worldwide incidence of hepatocellular carcinoma (HCC) continues to rise and liver transplantation (LT) represents an established curative treatment for early stage disease. As a result of organ shortage, guidelines have restricted transplantation to HCC patients with an expected 5-year post transplantation survival greater than 70 %. The Milan criteria (MC) remain a reliable and noninvasive instrument for selecting patients with 5-year survival meeting this criteria. Since the adoption of the MC by United Network for Organ Sharing (UNOS), attempts have been made to expand MC to account for the projected increase in the incidence of HCC over the next 20 years. An area of active debate focuses on identifying a subgroup of patients outside of MC with similar or better outcomes through either new expanded criteria or identifying other prognostic factors to enhance MC. 相似文献
54.
55.
56.
57.
58.
59.
60.
David D. Berg Muthiah Vaduganathan Gaurav A. Upadhyay Jagmeet P. Singh Mandeep R. Mehra Garrick C. Stewart 《Journal of the American College of Cardiology》2018,71(13):1483-1493
Recent progress and evolution in device engineering, surgical implantation practices, and periprocedural management have advanced the promise of durable support with left ventricular assist systems (LVAS) in patients with stage D heart failure. With greater uptake of LVAS globally, a growing population of LVAS recipients have pre-existing cardiac implantable electronic devices (CIEDs). Strategies for optimal clinical management of CIEDs in patients with durable LVAS are evolving, and clinicians will increasingly face complex decisions regarding implantation, programming, deactivation, and removal of CIEDs. Traditional decision-making pathways for CIEDs may not apply to LVAS-supported patients, as few patients die of arrhythmic causes and many arrhythmias may be well tolerated. Given limited data, treatment decisions must be individualized and made collaboratively among electrophysiologists, advanced heart failure specialists, and patients and their caregivers. Large, prospective, well-conducted studies are needed to better understand the contemporary utility of CIEDs in patients with newer-generation LVAS. 相似文献